The items below are highlights from the free newsletter, “Smart, useful, science stuff about COVID-19.” To receive newsletter issues daily in your inbox, sign up here. Please consider a monthly contribution to support this newsletter.
At Science magazine, Jon Cohen reports on progress made by two companies that are developing treatments called monoclonal antibodies for people infected with SARS-CoV-2. On 9/29/20, Regeneron Pharmaceuticals released early data from its ongoing placebo-controlled experiment showing that its monoclonal antibody “cocktail” reduced symptoms and the amount of virus in the nasal passages of infected patients, Cohen reports. To make these treatments, company researchers clone antibodies harvested from mice infected with the virus or from people who recover from COVID-19 (the cloning involves pulling out the genes that make the antibodies and then using them to grow bulk quantities in other rodent cells). A University of North Carolina, Chapel Hill, infectious diseases researcher